J07BB03 - Influenza, Live Attenuated |
Propably not porphyrinogenic |
PNP |
Important Information
Risk for gastrointestinal adverse events in the form decreased appetite motivates vigilance against insufficient intake of food, especially of carbohydrate.
Side effects
Decreased appetite is reported as a very common side effect and may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Based on the pharmacokineticsof the influeza vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Risk for gastrointestinal adverse events in the form decreased appetite motivates vigilance against insufficient intake of food, especially of carbohydrate.
Therapeutic characteristics
Prophylaxis of influenza in children and adolescents between 2-18 years.
The live attenuated influenza vaccine is for nasal administration and is given as one divided dose in both nostrils.
Metabolism and pharmacokinetics
The influenza vaccine is not metabolized by the Cytochrome P450 system.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Fluenz. (Last edition: 29.07. 2016).
|
|
Tradenames
Fluenz · Pandemisch 
Fluenz 
Fluenz · Pandemic Influenza 
Fluenz · Pandémiás influenza 
Fluenz 
Fluenz (trivalent) vaccine · Fluenz Tetra vaccine · Fluenz vaccine · FluMist Quadrivalent vaccine 
Fluenz · Pandemic influenza 
Fluenz 
Fluenz · Pandemic influenza 
Flumist 
Fluenz · Pandemic influenza 
Fluenz · Pandemic influenza 
Fluenz · Pandemic Influenza 
Fluenz · Pandemic influenza 
Fluenz · Pandemic influenza 
Fluenz · Pandemic Influenza 
Fluenz 
Fluenz · Fluenz Tetra · Pandemic influenza 
Vaccines